Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.23
GCI's Cash-to-Debt is ranked lower than
76% of the 184 Companies
in the Global Publishing industry.

( Industry Median: 2.29 vs. GCI: 0.23 )
Ranked among companies with meaningful Cash-to-Debt only.
GCI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.23  Med: N/A Max: No Debt
Current: 0.23
Equity-to-Asset 0.31
GCI's Equity-to-Asset is ranked lower than
80% of the 182 Companies
in the Global Publishing industry.

( Industry Median: 0.56 vs. GCI: 0.31 )
Ranked among companies with meaningful Equity-to-Asset only.
GCI' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.41 Max: 0.47
Current: 0.31
0.3
0.47
Interest Coverage 2.15
GCI's Interest Coverage is ranked lower than
70% of the 141 Companies
in the Global Publishing industry.

( Industry Median: 27.35 vs. GCI: 2.15 )
Ranked among companies with meaningful Interest Coverage only.
GCI' s Interest Coverage Range Over the Past 10 Years
Min: 2.15  Med: 455.44 Max: No Debt
Current: 2.15
Piotroski F-Score: 5
Altman Z-Score: 1.48
Beneish M-Score: -2.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 1.03
GCI's Operating Margin % is ranked lower than
57% of the 183 Companies
in the Global Publishing industry.

( Industry Median: 4.46 vs. GCI: 1.03 )
Ranked among companies with meaningful Operating Margin % only.
GCI' s Operating Margin % Range Over the Past 10 Years
Min: 1.03  Med: 8.27 Max: 9.78
Current: 1.03
1.03
9.78
Net Margin % 0.61
GCI's Net Margin % is ranked lower than
57% of the 184 Companies
in the Global Publishing industry.

( Industry Median: 2.67 vs. GCI: 0.61 )
Ranked among companies with meaningful Net Margin % only.
GCI' s Net Margin % Range Over the Past 10 Years
Min: 0.61  Med: 6.64 Max: 8.25
Current: 0.61
0.61
8.25
ROE % 1.95
GCI's ROE % is ranked higher than
53% of the 182 Companies
in the Global Publishing industry.

( Industry Median: 3.96 vs. GCI: 1.95 )
Ranked among companies with meaningful ROE % only.
GCI' s ROE % Range Over the Past 10 Years
Min: 1.95  Med: 16.89 Max: 43.39
Current: 1.95
1.95
43.39
ROA % 0.73
GCI's ROA % is ranked lower than
51% of the 188 Companies
in the Global Publishing industry.

( Industry Median: 2.04 vs. GCI: 0.73 )
Ranked among companies with meaningful ROA % only.
GCI' s ROA % Range Over the Past 10 Years
Min: 0.73  Med: 7.36 Max: 22
Current: 0.73
0.73
22
ROC (Joel Greenblatt) % 2.87
GCI's ROC (Joel Greenblatt) % is ranked lower than
61% of the 185 Companies
in the Global Publishing industry.

( Industry Median: 14.88 vs. GCI: 2.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GCI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 2.87  Med: 24.01 Max: 59.7
Current: 2.87
2.87
59.7
GuruFocus has detected 1 Warning Sign with Gannett Co Inc $GCI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GCI's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

GCI Guru Trades in Q2 2016

Jim Simons 506,200 sh (+648.82%)
Paul Tudor Jones 74,820 sh (+70.22%)
Jeremy Grantham 643,598 sh (+24.68%)
David Dreman Sold Out
Steven Cohen Sold Out
Murray Stahl 14,809 sh (-40.04%)
Joel Greenblatt 235,784 sh (-57.98%)
John Rogers 540,628 sh (-71.47%)
Pioneer Investments 104,451 sh (-81.53%)
» More
Q3 2016

GCI Guru Trades in Q3 2016

Chuck Royce 81,711 sh (New)
Murray Stahl 14,858 sh (+0.33%)
Joel Greenblatt Sold Out
Pioneer Investments 103,685 sh (-0.73%)
Jim Simons 481,896 sh (-4.80%)
John Rogers 510,371 sh (-5.60%)
Paul Tudor Jones 36,424 sh (-51.32%)
Jeremy Grantham 243,200 sh (-62.21%)
» More
Q4 2016

GCI Guru Trades in Q4 2016

Chuck Royce 225,556 sh (+176.04%)
Paul Tudor Jones 56,000 sh (+53.74%)
Murray Stahl 14,864 sh (+0.04%)
Jim Simons Sold Out
John Rogers Sold Out
Pioneer Investments 100,702 sh (-2.88%)
Jeremy Grantham 66,946 sh (-72.47%)
» More
Q1 2017

GCI Guru Trades in Q1 2017

Joel Greenblatt 29,118 sh (New)
Jim Simons 1,113,400 sh (New)
Chuck Royce 312,452 sh (+38.53%)
Murray Stahl 14,897 sh (+0.22%)
Pioneer Investments Sold Out
Jeremy Grantham Sold Out
Paul Tudor Jones 42,374 sh (-24.33%)
» More
» Details

Insider Trades

Latest Guru Trades with GCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Publishing » Publishing    NAICS: 511110    SIC: 2711
Compare:OTCPK:RZSMF, NYSE:NEWM, NYSE:TIME, OTCPK:TCLAF, NAS:TRNC, OTCPK:IDWM, NAS:SCHL, NAS:DJCO, NAS:VALU, NYSE:AHC, NYSE:LEE, OTCPK:YLWDF, OTCPK:TORSF, NYSE:MNI, NAS:EDUC, OTCPK:LMDCF, OTCPK:FRLF, OTCPK:GPIW, NYSE:MDP, NYSE:NYT » details
Traded in other countries:1G4.Germany,
Headquarter Location:USA
Gannett Co Inc provides media and marketing solutions. The Company is engaged in providing commercial printing, newswire, marketing and data services operations.

Top Ranked Articles about Gannett Co Inc

ReachLocal Joins Select Group of Facebook Marketing Partners
ReachLocal Attains LSA Certification for its Proven and Trusted Digital Marketing Solutions and Services for Local Businesses
WOODLAND HILLS, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- ReachLocal, a leader in powering online marketing for local businesses, today announced it is one of the first digital marketing companies to achieve LSA Certification.
The Local Search Association (LSA) created the LSA Certification Program to help local businesses evaluate and verify the business practices of marketing providers. The goal of the program is to help small businesses find reputable, transparent digital marketing partners, understand how to compare services and be confident in their expectations for results. â€œReachLocal is one of the first digital marketing providers to achieve LSA certification,” said Neg Norton, president, LSA. “LSA Certification provides small businesses with the confidence that ReachLocal has been thoroughly vetted and can deliver on their promise to help local businesses grow and operate better.”Companies that are “LSA Certified” have passed a rigorous review process and are deemed trustworthy. Unlike other certification programs that focus on subject matter expertise, LSA Certification examines company-wide policies and processes for digital marketing sales and fulfillment to ensure small businesses are partnering with companies that exhibit honest business practices. â€œAt ReachLocal, we strive to deliver long-term marketing and advertising results that help local businesses grow and be successful,” said Sharon Rowlands, CEO of ReachLocal. “LSA Certification validates our market approach, in which we adhere to strict ethical and industry standards resulting in successful marketing programs for thousands of ReachLocal customers.”About ReachLocal
ReachLocal helps local businesses grow and operate their business better with leading technology and expert service for our clients’ lead generation and conversion. A subsidiary of Gannett Company, Inc. (:GCI), ReachLocal is headquartered in Woodland Hills, Calif. and operates in four regions: Asia-Pacific, Europe, Latin America and North America. For more information, visit www.reachlocal.com.About LSA
The Local Search Association (LSA) is a more than 40-year-old not-for-profit industry association of media companies, agencies and technology providers who help businesses market to local consumers. LSA has about 300 members in roughly 20 countries and the Association helps these members realize the power of local and location-based marketing through conferences, consulting, insights, advocacy and more. The Association offers industry news and perspective on its blog, LSA Insider, as well as resources on LinkedIn, Twitter, Facebook, YouTube and SlideShare.
Media Contact:
Aimee L. Quemuel
Codey Communications
[email protected]
1-844-707-8955

Read more...
PhytoPain Pharma Reports Successful Pre-CTA Consultation With Health Canada for Its Phase I Trial With Cannabis

OTTAWA, ONTARIO--(Marketwired - Jun 28, 2016) - PhytoPain Pharma Inc. ("PhytoPain Pharma" or "PPP"), a subsidiary of GrowPros Cannabis Ventures Inc. ("GrowPros" or the "Company") (CSE:GCI), is pleased to announce a successful pre-CTA (Clinical Trial Application) consultation with the Therapeutic Products Directorate ("TPD") of Health Canada regarding its proposed Phase I clinical study of smoked cannabis. PhytoPain Pharma submitted for review by the regulators, a pre-CTA information package to brief TPD on the planned clinical study and the investigational drug and its comparator (placebo). Health Canada provided feedback and guidance on the Phase I trial's study population, placebo material, and neurological and cognitive assessment measures. PhytoPain Pharma is on track to finalize the clinical protocol and submit the CTA application to TPD. PPP will meet with its Clinical Advisory Board to discuss the guidance from Health Canada and work with a Phase I Clinical Research Organization to implement the recommendations. In addition, PhytoPain Pharma will submit an application for exemption under section 56 of the Controlled Drugs and Substances Act for its planned research on healthy subjects. "This is the first step in establishing a key clinical research program aimed at developing the use of inhaled Cannabis as a prescription drug and will provide physicians with evidence on the safety and efficacy of inhaled Cannabis which remains the most commonly preferred form of ingestion by Medical Cannabis Patients," stated Dr. Chamberland, Chief Scientific Officer and Regulatory Affairs. "I am encouraged at the speed and efficiency displayed by our team in achieving this measurable milestone in the development of our cannabis inhalation drug product. This further validates our belief that, as the regulatory environment surrounding cannabis prohibition continues to evolve, the need for standardised pharmaceutical style products will become the standard in Medicinal Cannabis for physicians, insurers, and regulators. This will position PhytoPain Pharma and GrowPros very favourably as the consumer market continues to develop." The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy. Forward-looking statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.





GrowPros Cannabis Ventures Inc.
Ryan Brown
Chief Executive Officer
(613) 421-8402
GrowPros Cannabis Ventures Inc.
Andre Audet
Executive Chairman
(613) 421-8402
GrowPros Cannabis Ventures Inc.
Dr. Guy Chamberland
Chief Scientific Officer and Regulatory Affairs
(514) 220-9225




Read more...
GrowPros Announces the Acquisition of Laboratoires Holizen Inc. and a $600,000 Non-Brokered Private Placement

OTTAWA, ONTARIO--(Marketwired - Jun 22, 2016) - GrowPros Cannabis Ventures Inc. ("GrowPros" or the "Company") (CSE:GCI) is pleased to announce the acquisition of the assets of Laboratoires Holizen Inc. ("Holizen") for $450,000. The acquisition will be funded by the $600,000 private placement (see below). These assets will be part of the Company's new wholly-owned subsidiary Agro-Tek Inc. and will form a new division of GrowPros' that specializes in the distribution of Natural Health Products ("NHP") and cosmetics. The transaction will provide the Company with an established product line and allow GrowPros to rapidly commercialize and distribute new NHPs and cosmetics through Holizen's strong distribution network. Acquisition Terms: GrowPros will be required to make a payment of $325,000 on signing the agreement, $50,000 on the 12 month anniversary of the agreement, $50,000 on the 24 month anniversary of the agreement and a final payment of $25,000 on the 36 month anniversary of the agreement. The Agro-Tek team has already commenced applications with different government institutions to access investment funds for developing a strategic growth plan for the sale and distribution of Holizen products to the rest of Canada and the United States in the next year. Asset Highlight GrowPros has acquired Holizen's existing customer base, inventory and natural product registration numbers. The acquisition of Holizen's assets by GrowPros will not change Holizen's daily activities. The current President of Holizen, Mrs. Francine St-Sauveur, and all of the company's employees and consultants will be retained by GrowPros. Mrs. St-Sauveur will assume the role and responsibility of the Chief Operating Officer of Agro-Tek. In her new role, Mrs. St-Sauveur will be responsible for day-to-day operations and client relations including the company's network of retail stores. Mr. André Rancourt was appointed as Chief Executive Officer of Agro-Tek and will take over the management of all of its divisions and partnerships. "The Board of Directors and I are delighted that Mr. Rancourt has agreed to accept this responsibility," said André Audet, Chairman. "He is someone with tremendous experience in the NHP retail market, his unquestioned work ethic, and integrity will prove to be of great value to the growth of the Company". Mr. Rancourt has worked in the food and NHP market for over 20 years and has established an extensive network of contacts. André will be responsible for the overall commercial strategy of Agro-Tek, licencing of innovative technologies, and future acquisitions to expand the Company's product lines and distribution capabilities. Holizen products are currently distributed in over 200 Natural health stores in Quebec. The company plans to launch an aggressive expansion to try and grow its market share of the 11.3 Billion dollar FFNHP (functional foods and Natural Health Products) market Place *stats Canada. Holizen was created in 2002 and has been producing and distributing high quality NHP and cosmetic products. In addition to its NHP line, Mrs. St-Sauveur created alliances with several highly reputable European laboratories to offer Egyptian spagyria products, certified organic skincare products, and a line of silicon-based supplements and gels. "Holizen owes its fame to the absolute quality and efficiency of its products, a long and established network of clients, and the dedication of its employees to serve clients with respect and promptness," stated Mrs. St-Sauveur. "The acquisition by GrowPros will allow the company to rapidly expand the distribution of its product lines across all of North America and continue to offer its clients innovative, effective, and high quality NHP and cosmetic products." Summary The acquisition and recent creation of the multiple subsidiaries will provide GrowPros with a diversified portfolio of companies operating in independent yet related fields. PhytoPain Pharma Inc. will focus on pharmaceutical development, Agro-Tek will focus on retail product distribution and Grow Pros MMP will focus on cultivation and production of medicinal plants including Cannabis for which the company requires an approval under the Marijuana for Medical Purposes Regulation ("MMPR"). "This platform should allow GrowPros to evolve into a fully integrated Pharmaceutical and Natural Health product development, production, and distribution company. This strategy provides multiple revenue streams across various industry segments and sub segments and insulates the company from the uncertainty that results from solely focusing on an MMPR application," stated Ryan Brown, GrowPros CEO. Financial Terms: The Company also announces a non-brokered private placement of 12,000,000 units at a price of $0.05 per unit for aggregate gross proceeds of up to $600,000. Each unit will consist of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share at a price of $0.07 for a period of 12 months following the closing date. In connection with the private placement, the Company may pay a cash finder's fee equal to 8% of the gross proceeds raised and may issue non-transferable finder's warrants equal to 8% of the number of common shares issued under the private placement. Each finder's warrant will entitle the holder to purchase one common share of the Company at a price of $0.07 per share for a period of 12 months following the closing of the private placement. The securities issued pursuant to the private placement will be subject to a four-month hold period from the closing date. The Company may pay a commission in connection with the private placement, subject to compliance with the policies of the Exchange. Completion of the private placement and the payment of any commissions remain subject to the receipt of all necessary regulatory approvals, including the approval of the Exchange. The proceeds of the private placement will be used to fund the acquisition of the assets of Holizen as well as general working capital. The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy. Forward-looking statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.





GrowPros Cannabis Ventures Inc.
Ryan Brown
Chief Executive Officer
(613) 421-8402
GrowPros Cannabis Ventures Inc.
Andre Audet
Executive Chairman
(613) 421-8402
GrowPros Cannabis Ventures Inc.
Dr. Guy Chamberland
Chief Scientific Officer and Regulatory Affairs
(514) 220-9225




Read more...
GrowPros Launches AGORACOM Online Marketing and Awareness Program

OTTAWA, ONTARIO--(Marketwired - Jun 20, 2016) - GrowPros Cannabis Ventures Inc. ("GrowPros" or the "Company") (CSE:GCI) is pleased to announce that it is implementing an online marketing and awareness program through AGORACOM. GrowPros will significantly expand its exposure through millions of content brand insertions on the AGORACOM network and extensive search engine marketing over the next 12 months. In addition, exclusive sponsorships of invaluable digital properties such as AGORACOM TV, the AGORACOM home page, and the AGORACOM Twitter account will serve to significantly raise the brand awareness of the Company among small cap investors. Ryan Brown, Chief Executive Officer commented: "AGORACOM has proven to be a leader in the online marketing space. We are delighted to have retained their services to expand our online presence." Shares for Services Program GrowPros intends to issue shares for services to AGORACOM in exchange for the online advertising, marketing, and branding services ("Advertising Services"). Pursuant to the terms of the agreement, the Company will be issuing:

$CDN 44,000 HST
$10,000 HST Shares for services June 20, 2016
$10,000 HST Shares For Advertising Services at end of Third Month September 20, 2016
$10,000 HST Shares For Advertising Services at end of Sixth Month December 20, 2016
$10,000 HST Shares For Advertising Services at end of Ninth Month March 20, 2017
$4,000 HST Shares For Advertising Services at end of Twelfth Month June 20, 2017

The number of shares to be issued at the end of each period will be determined by using the closing price of the Shares of GrowPros on the Canadian Securities Exchange on the first trading day following each period for which the Advertising Services were provided by AGORACOM. The agreement/arrangement is subject to exchange approval. The term of the Agreement is for 12 months effective immediately. GrowPros will issue a press release after the issuance of shares under the terms of the agreement. About AGORACOM AGORACOM is the pioneer of online investor relations, online conferences, and online branding services to North American small and mid-cap public companies, with more than 250 companies served. More than just lip service, AGORACOM is the home of more than 808K investors that visited 5.6 million times and read 52.4 million pages of information every year (Average 2008 - 2015). AGORACOM traffic ranks within the top 0.5% of all websites around the world. These traffic results are independently tracked and verified by Google analytics. AGORACOM traffic can be attributed to its strategy of maintaining the cleanest, moderated small-cap discussion as a result of implementing the first ever Investor Controlled Stock Discussion Forums. AGORACOM Founder, George Tsiolis, publishes the leading blog on small to mid-cap investor relations. His 50 Small-Cap CEO Lessons are a must read for CEO's looking to increase their education and knowledge about online investor relations. The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy. Forward-looking statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.





GrowPros Cannabis Ventures Inc.
Ryan Brown
Chief Executive Officer
(613) 421-8402




Read more...
PhytoPain Pharma Files Clinical Trial Application (CTA) for a Topical Product for the Treatment of Chemotherapy-Induced Neuropathic Pain

OTTAWA, ONTARIO--(Marketwired - Jun 15, 2016) - PhytoPain Pharma (PPP) Inc., a subsidiary of GrowPros Cannabis Ventures Inc. ("GrowPros" or the "Company" or "GCI") (CSE:GCI), today announced that it has filed a Clinical Trial Application (CTA) with Health Canada for PhytoPain Topical Gel Relief (PPTGR), a locally administered therapeutic for the treatment of chemotherapy-induced neuropathic pain (CINP). Upon approval of the CTA, the Company plans to initiate a double-blind, randomized, cross-over, placebo-controlled clinical study with PPTGR in late 2016 and expects to report initial clinical data from the trial in late 2017.
CINP is a common adverse effect of cancer therapy and a frequent reason why cancer patients stop their treatment early. For some patients, the severity of the symptoms can be reduced by lowering the dose of chemotherapy or temporarily stopping it. In other patients, the symptoms of CINP may last for months or years after the cancer therapy has stopped. CINP symptoms are managed using the same analgesics used to manage other types of neuropathic pain. Some of these analgesics also cause intolerable side effects in patients. The use of a topical counterirritant may help reduce the symptoms of CINP and avoid exposing some patients to oral neuropathic pain analgesics.
According to Dr. Guy Chamberland, the Company's Chief Scientific Officer, "PPP is developing this topical product to provide cancer patients a safer, natural and more tolerable alternative in the management of CINP". The development of the PPTGR product is in line with PPP's strategy to bring an integrative medical approach for cancer patients suffering from pain. "The demonstration of the safety and efficacy of botanical drugs including cannabis for pain management is a critical step in the development of an evidence-based approach to integrative medical care. PPP intends on working with physicians to demonstrate that PPTGR can be safely used as an adjunct to inhalation and oral medical marijuana for the reduction of pain in cancer patients. Physicians need additional drugs that can help reduce the amount of narcotics required to manage pain while minimizing the risk of psycho active effects or tolerance to opioids, cannabis, and other narcotics commonly prescribed to patients. The intention is to develop PPTGR, and other botanical-based drugs, as adjuncts to the standard of care," stated Dr. Chamberland.
PPTGR is a counterirritant topical gel that conforms to the Natural and Non-prescription Health Products Directorate (NNHPD) monograph. However, the intended use of counterirritant products under the NNHPD monograph does not include the temporary relief of CINP. PPP is launching a clinical trial to demonstrate the safety and efficacy of PPTGR in cancer patients with CINP and work with medical oncologists to integrate the use of PPTGR in the management of CINP.
International research indicates that 60% of patients undergoing chemotherapy will suffer from varying degrees of CINP during their treatment. PPP believes it can demonstrate increased symptom alleviation using natural based agents and mixtures as opposed to the synthetic alternatives. "PPP was created to conduct cannabinoid and medicinal plant based research with the goal of developing over-the-counter products for consumers and prescription drug products for physicians that can be distributed through the existing pharmaceutical infrastructure. This submission is the first step in the growth of our vision," commented CEO Ryan Brown.
CINP Market Size and comparison products
MARKET STATISTICS: There were an estimated 15.2 million cancer cases globally in 2014 according to the International Agency for Research on Cancer (IARC) with projections of 17.1 million cases in 2020. Roughly 25%-30% of cancer patients receive chemotherapy, and of those patients, 70%-80% experience a form of CINP. The global CINP market saw estimated revenue of $1.3 billion in 2014 with a projected 5.7% compounded annual growth rate through 2020 as cancer rates climb with growing, aged populations. Of the products available Oral delivery drug of dronabinol which is comprised of synthetic cannabinoids had sales of $110M in 2014. Similar to other mainly orally administered cannabinoids, results in relatively low bioavailability, coupled with irregular pharmacokinetics secondary to absorption variability and first-pass metabolism by the liver, complicated by the need for multiple dosages per day. In addition, many patients report nausea and/or vomiting as a side-effect related to the drug. (NEMUS BIO SCIENCE)
Many studies have concluded that natural cannabinoids offer a safer, more effective solution than their synthetic counterparts. A recent article entitled Comparison of Outcome Expectancies for Synthetic Cannabinoids and Botanical Marijuana, from The American Journal of Drug and Alcohol Abuse, concluded that given growing public acceptance of recreational and medical marijuana, coupled with negative perceptions and increasing regulation of synthetic cannabinoid compounds, botanical marijuana is likely to remain more available and more popular than synthetic cannabinoids. "PPP is proud to position itself as a leader in the development of natural pharmaceuticals derived Cannabis and other medicinal plants," commented CEO Ryan Brown. The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.





GrowPros Cannabis Ventures Inc.
Ryan Brown
Chief Executive Officer
(613) 421-8402
GrowPros Cannabis Ventures Inc.
Andre Audet
Executive Chairman
(613) 421-8402
GrowPros Cannabis Ventures Inc.
Dr. Guy Chamberland
Chief Scientific Officer and Regulatory Affairs
(514) 220-9225




Read more...
GrowPros Announces Creation of PhytoPain Pharma, a New Subsidiary

OTTAWA, ONTARIO--(Marketwired - Jun 2, 2016) - GrowPros Cannabis Ventures Inc. ("GrowPros" or the "Company" or "GCI") (CSE:GCI) is pleased to announce the creation of a new subsidiary PhytoPain Pharma Inc. ("PPP"). PPP will be owned 80% by GCI and with 20% owned by Dr. Guy Chamberland, M.Sc., Ph.D. and Mr. André Rancourt as co-founders with GCI. The mission of PPP is the development and commercialization of botanical based pharmaceuticals. PPP is a clinical-stage drug development company engaged in the development of medication to alleviate symptoms related to pain, Insomnia and anxiety disorders in patients suffering from Cancer and other chronic and terminal diseases that cause uncontrolled pain and or insomnia. PPP has submitted a pre-CTA (Clinical Trial Applications) information package to the Therapeutics Drug Directorate (TPD). As agreed with TPD, Health Canada will provide guidance to PPP's planned Phase I clinical trial of its lead product, an inhalation cannabis drug product. The company intends on initiating the Phase I clinical trial later this year. PPP is developing this product as a prescription controlled drug for the management of uncontrolled pain in cancer patients. PPP has licenced a hypnotic drug from Mondias Naturals Inc for the management of insomnia in patients with chronic pain. This latter product is currently in late stage (Phase III) clinical testing. PPP is currently developing a combination product for the treatment of uncontrolled pain. The proprietary combination product should reach clinical testing in 2017. GrowPros announced today that Dr. Guy Chamberland, M.Sc., Ph.D., was appointed as Chief Scientific Officer and will take over the role of drug development and regulatory affairs. "The Board of Directors and I are delighted that Guy has agreed to join PPP," said André Audet, Chairman. "Guy is someone with tremendous expertise in drug development and specifically the development of botanical drugs and combination products, his unquestioned intellect, work ethic, and integrity will prove to be of great value to the GCI organization and its shareholders." Dr. Chamberland has worked over 22 years in the pharmaceutical and natural product industries and is also a professor of herbal medicine and clinical research at the École d'Enseignement Supérieur de Naturopathie du Québec. He has successfully developed intellectual property for several botanical drug products and has managed numerous development programs and worked closely with marketing teams to develop physician education programs. GCI is also announcing today that André Rancourt was appointed as the Vice President Corporate Development and will take over the strategic and licencing operations of PPP. Mr. Rancourt is highly experienced in management, start-up companies, and commercial strategies for human and agriculture products. He has developed an expertise in the area of negotiation and has successfully negotiated collective agreements for Station Radiophonique Régional de Télémédia Québec as well as agreements for companies in the metal and Agro-Food businesses. In addition, he negotiated license agreements as well as several technology transfers. Over the last ten years, Mr. Rancourt worked as a consultant to re-organize the operations of companies on behalf of several venture capital investment funds. "André is someone with tremendous expertise in negotiation and has a vast network of contacts in the industry. His dedication and work ethic will benefit the PPP organization and its shareholders. The Board of Directors and I are excited that André is joining PPP to help the corporation become a world leader in botanical drugs," commented André Audet, Chairman. Subject to regulatory approval, Mr. Rancourt and Dr. Chamberland will each receive from GrowPros:

upon submission of pre-CTA information package: 1,250,000 options at $0.05 for 5 years and 750,000 common shares warrants at $0.05 for 1 year;
upon commencement of Phase 1 clinical trials of PPP0001: 2,000,000 common shares warrants at $0.05 for 2 years; and
upon successful completion of Phase 1 clinical trials of PPP0001: 2,000,000 common shares warrants at $0.05 for 3 years

"The creation of PPP provides GCI with a clear and defined approach to medicinal cannabis product development. GCI 's subsidiaries will now be able to collaborate on the development and design of a cannabis production facility designed to produce the standardized raw material that PPP will require to develop and bring their inhalation cannabis drug product to market. Rather than being another applicant producer vying for a piece of an already oversaturated ever changing dried flower and cannabis oils market, we will now focus on creating licensed protected pharmaceutical and natural health products containing cannabis and other medicinal plants," commented Ryan Brown, Chief Executive Officer. Update on application GCI is finalising technical plans for its revised 12,500 sq. ft. two-storey production facility to be built in conjunction with Delta 9 Bio-Tech Inc. ("Delta 9") a licensed producer under the Marijuana for Medical Purposes Regulation ("MMPR"). As previously announced, Delta 9 will be submitting an application to build a secondary production facility under section 26 of the MMPR. As per the terms of the agreement, GCI will acquire the license from Delta 9 in exchange for $2,000,000 in stock payable in 5 equal payments upon milestone completions. The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy. Forward-looking statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.





GrowPros Cannabis Ventures Inc.
Ryan Brown
Chief Executive Officer
(613) 421-8402
GrowPros Cannabis Ventures Inc.
Andre Audet
Executive Chairman
(613) 421-8402
GrowPros Cannabis Ventures Inc.
Dr. Guy Chamberland
Chief Scientific Officer and Regulatory Affairs
(514) 220-9225




Read more...

Ratios

vs
industry
vs
history
PE Ratio 52.13
GCI's PE Ratio is ranked lower than
52% of the 122 Companies
in the Global Publishing industry.

( Industry Median: 18.76 vs. GCI: 52.13 )
Ranked among companies with meaningful PE Ratio only.
GCI' s PE Ratio Range Over the Past 10 Years
Min: 7.01  Med: 13.24 Max: 59.4
Current: 52.13
7.01
59.4
Forward PE Ratio 8.36
GCI's Forward PE Ratio is ranked higher than
79% of the 75 Companies
in the Global Publishing industry.

( Industry Median: 14.66 vs. GCI: 8.36 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 52.13
GCI's PE Ratio without NRI is ranked higher than
50% of the 121 Companies
in the Global Publishing industry.

( Industry Median: 19.00 vs. GCI: 52.13 )
Ranked among companies with meaningful PE Ratio without NRI only.
GCI' s PE Ratio without NRI Range Over the Past 10 Years
Min: 7.01  Med: 13.24 Max: 59.4
Current: 52.13
7.01
59.4
PB Ratio 1.04
GCI's PB Ratio is ranked higher than
58% of the 179 Companies
in the Global Publishing industry.

( Industry Median: 1.42 vs. GCI: 1.04 )
Ranked among companies with meaningful PB Ratio only.
GCI' s PB Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.41 Max: 1.91
Current: 1.04
0.86
1.91
PS Ratio 0.29
GCI's PS Ratio is ranked higher than
84% of the 178 Companies
in the Global Publishing industry.

( Industry Median: 1.03 vs. GCI: 0.29 )
Ranked among companies with meaningful PS Ratio only.
GCI' s PS Ratio Range Over the Past 10 Years
Min: 0.27  Med: 0.51 Max: 0.71
Current: 0.29
0.27
0.71
Price-to-Free-Cash-Flow 8.70
GCI's Price-to-Free-Cash-Flow is ranked higher than
59% of the 76 Companies
in the Global Publishing industry.

( Industry Median: 12.69 vs. GCI: 8.70 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GCI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.1  Med: 9.37 Max: 16.67
Current: 8.7
6.1
16.67
Price-to-Operating-Cash-Flow 5.37
GCI's Price-to-Operating-Cash-Flow is ranked higher than
71% of the 97 Companies
in the Global Publishing industry.

( Industry Median: 9.88 vs. GCI: 5.37 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GCI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.84  Med: 6.39 Max: 11.23
Current: 5.37
4.84
11.23
EV-to-EBIT 39.30
GCI's EV-to-EBIT is ranked higher than
51% of the 182 Companies
in the Global Publishing industry.

( Industry Median: 15.54 vs. GCI: 39.30 )
Ranked among companies with meaningful EV-to-EBIT only.
GCI' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.1  Med: 9.5 Max: 43.4
Current: 39.3
5.1
43.4
EV-to-EBITDA 6.41
GCI's EV-to-EBITDA is ranked higher than
78% of the 204 Companies
in the Global Publishing industry.

( Industry Median: 11.05 vs. GCI: 6.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
GCI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.6  Med: 5.9 Max: 8.6
Current: 6.41
3.6
8.6
Current Ratio 1.11
GCI's Current Ratio is ranked lower than
71% of the 170 Companies
in the Global Publishing industry.

( Industry Median: 1.64 vs. GCI: 1.11 )
Ranked among companies with meaningful Current Ratio only.
GCI' s Current Ratio Range Over the Past 10 Years
Min: 0.95  Med: 1.22 Max: 1.32
Current: 1.11
0.95
1.32
Quick Ratio 1.11
GCI's Quick Ratio is ranked lower than
66% of the 170 Companies
in the Global Publishing industry.

( Industry Median: 1.30 vs. GCI: 1.11 )
Ranked among companies with meaningful Quick Ratio only.
GCI' s Quick Ratio Range Over the Past 10 Years
Min: 0.88  Med: 1.14 Max: 1.26
Current: 1.11
0.88
1.26
Days Inventory 5.94
GCI's Days Inventory is ranked higher than
85% of the 152 Companies
in the Global Publishing industry.

( Industry Median: 32.43 vs. GCI: 5.94 )
Ranked among companies with meaningful Days Inventory only.
GCI' s Days Inventory Range Over the Past 10 Years
Min: 4.32  Med: 6.23 Max: 8.07
Current: 5.94
4.32
8.07
Days Sales Outstanding 37.42
GCI's Days Sales Outstanding is ranked higher than
80% of the 138 Companies
in the Global Publishing industry.

( Industry Median: 69.27 vs. GCI: 37.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
GCI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 37.42  Med: 42.29 Max: 42.88
Current: 37.42
37.42
42.88
Days Payable 32.50
GCI's Days Payable is ranked lower than
78% of the 120 Companies
in the Global Publishing industry.

( Industry Median: 83.64 vs. GCI: 32.50 )
Ranked among companies with meaningful Days Payable only.
GCI' s Days Payable Range Over the Past 10 Years
Min: 18.02  Med: 25.68 Max: 33.96
Current: 32.5
18.02
33.96

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 8.18
GCI's Dividend Yield % is ranked higher than
89% of the 216 Companies
in the Global Publishing industry.

( Industry Median: 3.14 vs. GCI: 8.18 )
Ranked among companies with meaningful Dividend Yield % only.
GCI' s Dividend Yield % Range Over the Past 10 Years
Min: 0.93  Med: 4.63 Max: 8.63
Current: 8.18
0.93
8.63
Dividend Payout Ratio 7.11
GCI's Dividend Payout Ratio is ranked lower than
94% of the 95 Companies
in the Global Publishing industry.

( Industry Median: 0.43 vs. GCI: 7.11 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GCI' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.86 Max: 7.11
Current: 7.11
0.26
7.11
Forward Dividend Yield % 8.18
GCI's Forward Dividend Yield % is ranked higher than
91% of the 207 Companies
in the Global Publishing industry.

( Industry Median: 2.97 vs. GCI: 8.18 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 8.19
GCI's 5-Year Yield-on-Cost % is ranked higher than
85% of the 282 Companies
in the Global Publishing industry.

( Industry Median: 3.53 vs. GCI: 8.19 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GCI' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.93  Med: 4.63 Max: 8.63
Current: 8.19
0.93
8.63

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 868.89
GCI's Price-to-Tangible-Book is ranked lower than
99% of the 140 Companies
in the Global Publishing industry.

( Industry Median: 1.67 vs. GCI: 868.89 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GCI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.85  Med: 4.39 Max: 931.11
Current: 868.89
3.85
931.11
Price-to-Median-PS-Value 0.57
GCI's Price-to-Median-PS-Value is ranked higher than
88% of the 153 Companies
in the Global Publishing industry.

( Industry Median: 1.06 vs. GCI: 0.57 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GCI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.09 Max: 1.29
Current: 0.57
0.57
1.29
Price-to-Graham-Number 46.00
GCI's Price-to-Graham-Number is ranked lower than
98% of the 83 Companies
in the Global Publishing industry.

( Industry Median: 1.33 vs. GCI: 46.00 )
Ranked among companies with meaningful Price-to-Graham-Number only.
GCI' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.23  Med: 1.61 Max: 49.29
Current: 46
1.23
49.29
Earnings Yield (Greenblatt) % 2.54
GCI's Earnings Yield (Greenblatt) % is ranked higher than
67% of the 271 Companies
in the Global Publishing industry.

( Industry Median: 3.75 vs. GCI: 2.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GCI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.3  Med: 10.6 Max: 19.7
Current: 2.54
2.3
19.7

More Statistics

Revenue (TTM) (Mil) $3,162
EPS (TTM) $ 0.15
Short Percentage of Float10.81%
52-Week Range $7.30 - 15.93
Shares Outstanding (Mil)113.61

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3,202 3,023 2,872
EPS ($) 0.94 1.06 0.96
EPS without NRI ($) 0.94 1.06 0.96
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for GCI

Headlines

Articles On GuruFocus.com
ReachLocal Joins Select Group of Facebook Marketing Partners May 10 2017 
ReachLocal Attains LSA Certification for its Proven and Trusted Digital Marketing Solutions and Serv Mar 23 2017 
Smead Value Fund 4th Quarter Shareholder Letter Mar 07 2017 
ReachLocal Named a Top Web Marketing Provider by FranchiseRankings.com Jan 26 2017 
Big Declines: 4 3rd-Quarter Earnings Losers Nov 11 2016 
Bill Smead's Smead Value Fund 3rd Quarter Commentary Oct 25 2016 
Pearson, FTD and Gannett are on the Casualty List Oct 06 2016 
3 Ways to Spot and Avoid Value Traps Sep 30 2016 
52-Week Company Lows Aug 25 2016 
Companies Fall to 52-Week Lows Aug 11 2016 

More From Other Websites
Gannett (GCI) Down 15.3% Since Earnings Report: Can It Rebound? May 26 2017
Which Media Firms Are Benefiting Most From President Trump? May 25 2017
The 2 Best Dividend Stocks in Newspapers May 22 2017
​Journal Sentinel property buyer acquires Press-Gazette, Northwestern offices May 19 2017
ETFs with exposure to Gannett Co., Inc. : May 18, 2017 May 18 2017
ReachLocal Customer All Dry USA Wins Coveted Stevie Award in the Home Supplies and Services... May 18 2017
Newspaper Companies Take Pounding From Wall Street May 18 2017
Gannett to Participate in the J.P. Morgan 2017 Global Technology, Media and Telecom Conference May 16 2017
Gannett Co., Inc. :GCI-US: Earnings Analysis: Q1, 2017 By the Numbers : May 16, 2017 May 16 2017
[$$] Chicago Tribune Owner Makes Bid to Buy Sun-Times May 15 2017
'VRtually There' Season Two Makes USA Today The Leading 360 VR News Producer May 11 2017
Gannett Co., Inc. breached its 50 day moving average in a Bearish Manner : GCI-US : May 11, 2017 May 11 2017
Gannett Announces Results of Annual Meeting; Board Declares Regular Quarterly Dividend May 10 2017
ReachLocal Joins Select Group of Facebook Marketing Partners May 10 2017
USA TODAY NETWORK Continues To Push Boundaries in VR Storytelling with Release of Season Two of... May 09 2017
USA Today owner Gannett warns workers of possible breach May 02 2017
[$$] Gannett Reports Data Breach Compromising Employee Information May 02 2017
Tribune Leads Media Stocks' Surge in Trump's First 100 Days, as Fox Trails the Pack Apr 29 2017
Edited Transcript of GCI earnings conference call or presentation 25-Apr-17 2:00pm GMT Apr 29 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)